These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

358 related items for PubMed ID: 20074463

  • 1. Acute rejection features in dual kidney transplant recipients from elderly donors: comparison of calcineurin inhibitor-based and calcineurin inhibitor-free immunosuppressive protocols.
    Aiello FB, Furian L, Marino S, Marchini F, Cardillo M, De Fazio N, Rigotti P, Valente M.
    Int J Immunopathol Pharmacol; 2009; 22(4):1001-7. PubMed ID: 20074463
    [Abstract] [Full Text] [Related]

  • 2. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS, Irfan Saeed M, Ranganna K, Malat G, Sustento-Reodica N, Kumar AM, Meyers WC.
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [Abstract] [Full Text] [Related]

  • 3. Renin-Angiotensin System Blockage and Avoiding High Doses of Calcineurin Inhibitors Prevent Interstitial Fibrosis and Tubular Atrophy in Kidney Transplant Recipients.
    Sayin B, Canver B, Gurlek Demirci B, Colak T, Ozdemir BH, Haberal M.
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):32-36. PubMed ID: 28260428
    [Abstract] [Full Text] [Related]

  • 4. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ, Feustel PJ, Elbahloul O, Conti AD, Gallichio MH, Conti DJ.
    Clin Transplant; 2007 Feb; 21(1):101-9. PubMed ID: 17302598
    [Abstract] [Full Text] [Related]

  • 5. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
    Uslu A, Nart A, Taşli FA, Postaci H, Aykas A, Doğan M, Sahin T.
    Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
    [Abstract] [Full Text] [Related]

  • 6. A Banff Component Scoring-based Histologic Assessment of Bortezomib-based Antibody-mediated Rejection Therapy.
    Sadaka B, Ejaz NS, Shields AR, Cardi MA, Wadih G, Witte D, Abu Jawdeh BG, Alloway RR, Woodle ES.
    Transplantation; 2015 Aug; 99(8):1691-9. PubMed ID: 25803498
    [Abstract] [Full Text] [Related]

  • 7. Clinicopathologic analysis of acute vascular rejection cases after renal transplantation.
    Shimizu T, Tanabe T, Omoto K, Ishida H, Tanabe K.
    Transplant Proc; 2012 Jan; 44(1):230-5. PubMed ID: 22310621
    [Abstract] [Full Text] [Related]

  • 8. Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus.
    de Sandes-Freitas TV, Felipe CR, Campos ÉF, de Lima MG, Soares MF, de Franco MF, Aguiar WF, Tedesco-Silva H, Medina-Pestana JO.
    Transplantation; 2015 Nov; 99(11):2372-81. PubMed ID: 25929604
    [Abstract] [Full Text] [Related]

  • 9. Calcineurin inhibitor-free immunosuppression in dual kidney transplantation from elderly donors.
    Furian L, Baldan N, Margani G, Ekser B, Silvestre C, Marchini F, Bonfante L, Rossi B, Valente ML, Rigotti P.
    Clin Transplant; 2007 Nov; 21(1):57-62. PubMed ID: 17302592
    [Abstract] [Full Text] [Related]

  • 10. Optimizing Immunosuppressive Regimens Among Living-Donor Renal Transplant Recipients.
    Bakr MA, Nagib AM, Gheith OA, Hamdy AF, Refaie AF, Donia AF, Neamatalla AH, Eldahshan KF, Denewar AA, Abbas MH, Mostafa AI, Ghoneim MA.
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):16-23. PubMed ID: 28260425
    [Abstract] [Full Text] [Related]

  • 11. C4D deposition and positive posttransplant crossmatch are not necessarily markers of antibody-mediated rejection in renal allograft recipients.
    Banasik M, Boratyńska M, Nowakowska B, Haloń A, Kościelska-Kasprzak K, Drulis-Fajdasz D, Patrzałek D, Weyde W, Klinger M.
    Transplant Proc; 2007 Nov; 39(9):2718-20. PubMed ID: 18021967
    [Abstract] [Full Text] [Related]

  • 12. Peritubular capillary C4d staining in late acute renal allograft rejection--is it relevant?
    Satoskar AA, Lehman AM, Nadasdy GM, Sedmak DD, Pesavento TE, Henry ML, Pelletier RP, Ferguson RM, Nadasdy T.
    Clin Transplant; 2008 Nov; 22(1):61-7. PubMed ID: 18217907
    [Abstract] [Full Text] [Related]

  • 13. Alemtuzumab preconditioning allows steroid-calcineurin inhibitor-free regimen in live-donor kidney transplant.
    Refaie AF, Mahmoud KM, Ismail AM, Sheashaa HA, Kamal AI, Ghoneim MA.
    Exp Clin Transplant; 2011 Oct; 9(5):295-301. PubMed ID: 21967254
    [Abstract] [Full Text] [Related]

  • 14. High frequency of rejections in HIV-positive recipients of kidney transplantation: a single center prospective trial.
    Malat GE, Ranganna KM, Sikalas N, Liu L, Jindal RM, Doyle A.
    Transplantation; 2012 Nov 27; 94(10):1020-4. PubMed ID: 23169224
    [Abstract] [Full Text] [Related]

  • 15. Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantation.
    Knight RJ, Podder H, Kerman RH, Lawless A, Katz SM, Van Buren CT, Gaber AO, Kahan BD.
    Transplantation; 2010 Mar 27; 89(6):727-32. PubMed ID: 20195219
    [Abstract] [Full Text] [Related]

  • 16. Increased C4d in post-reperfusion biopsies and increased donor specific antibodies at one-week post transplant are risk factors for acute rejection in mild to moderately sensitized kidney transplant recipients.
    Djamali A, Muth BL, Ellis TM, Mohamed M, Fernandez LA, Miller KM, Bellingham JM, Odorico JS, Mezrich JD, Pirsch JD, D'Alessandro TM, Vidyasagar V, Hofmann RM, Torrealba JR, Kaufman DB, Foley DP.
    Kidney Int; 2013 Jun 27; 83(6):1185-92. PubMed ID: 23447068
    [Abstract] [Full Text] [Related]

  • 17. Immunosuppressive regimen and interstitial fibrosis and tubules atrophy at 12 months postrenal transplant.
    Gelens MA, Steegh FM, van Hooff JP, van Suylen RJ, Nieman FH, van Heurn LW, Peutz-Kootstra CJ, Christiaans MH.
    Clin J Am Soc Nephrol; 2012 Jun 27; 7(6):1010-7. PubMed ID: 22490875
    [Abstract] [Full Text] [Related]

  • 18. Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant.
    Rivelli RF, Gonçalves RT, Leite M, Santos MA, Delgado AG, Cardoso LR, Takiya CM.
    Nephrology (Carlton); 2015 Mar 27; 20(3):168-76. PubMed ID: 25404086
    [Abstract] [Full Text] [Related]

  • 19. De novo development of circulating anti-endothelial cell antibodies rather than pre-existing antibodies is associated with post-transplant allograft rejection.
    Sun Q, Cheng Z, Cheng D, Chen J, Ji S, Wen J, Zheng C, Liu Z.
    Kidney Int; 2011 Mar 27; 79(6):655-662. PubMed ID: 20980975
    [Abstract] [Full Text] [Related]

  • 20. Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function.
    Weir MR, Blahut S, Drachenburg C, Young C, Papademitriou J, Klassen DK, Cangro CB, Bartlett ST, Fink JC.
    Am J Nephrol; 2004 Mar 27; 24(4):379-86. PubMed ID: 15237243
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.